[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100637069":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":26,"responsibleParty":42,"collaborators":10,"id":44,"slug":10,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":45,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":10,"studyType":56,"phases":10,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":66,"whyStopped":10,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"University Hospital, Lille","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Ofatumumab",null,"Adult patients (≥18 years) with relapsing multiple sclerosis treated with ocrelizumab for at least 18 months and already switched or switching from ocrelizumab to ofatumumab treatment",[13],"Drug: ofatumumab",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","ofatumumab","There is no treatment allocation. Participants with MS that initiated treatment with ofatumumab (Kesimpta ®) as per neurologist practice and regardless of the study protocol.",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"PATRICK VERMERSCH, Pr","CONTACT","06.33.38.32.60","patrick.vermersch@chu-lille.fr",[27],{"facility":28,"status":10,"city":29,"state":10,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"CHU de Lille","Lille","59000","France","FR",{"type":34,"coordinates":35},"Point",[36,37],3.05512,50.63391,{"lat":37,"lon":36},[40],{"name":41,"role":23,"phone":24,"phoneExt":10,"email":25},"Patrick VERMERSCH, Dr",{"type":43,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100637069",false,"NCT07625800","Switch to Ofatumumab and Level of Immunoglobulins","SOLI","Inclusion Criteria:\n\n1. Adult patients (≥ 18 years old) who had been treated with ocrelizumab for a relapsing form of Multiple Sclerosis according to the ocrelizumab marketing authorization (MA) treatment regimen for at least 18 months.\n2. Patients with a decrease of IgG at a minimum of two consecutive dosages (around six months apart) during ocrelizumab treatment\\*.\n3. Patients already switched or switching from ocrelizumab to ofatumumab treatment (decision independent from the study\\*).\n4. Patients agreeing to participate to the study.\n5. Able to provide their non-opposition\n\n   * At the discretion of the investigator, if a benefit for patients is expected based on their experience and depending on patient's characteristics\n\nExclusion Criteria:\n\n1. Patients with ocrelizumab dose spacing \\> 8 months in the last 18 months before switch\n2. Patient who underwent an immunoglobulin supplementation therapy within 18 months before the switch\n3. Ongoing or planned pregnancy","ALL","18 Years","65 Years",{"count":54,"type":55},115,"ESTIMATED","OBSERVATIONAL","This real-life study aims to describe IgG levels after switching from ocrelizumab 600 mg IV every 6 to 8 months in Patients with Multiple Sclerosis (PwMS) to ofatumumab 20 mg SC every month and showing a decreasing level of IgG during treatment by ocrelizumab in real life practice in France over 24 months of follow-up.\n\nThe primary objective is therefore to determine if the downward trend of IgG observed during ocrelizumab treatment is modified after a switch to ofatumumab, in PwMS treated during at least 18 months of ocrelizumab in real life practice, over 24 months of follow-up.",[59],"Multiple Sclerosis",[59,61,9,62,63,64,65],"NIS","Kesimpta","Ocrelizumab","IgG","IgM","NOT_YET_RECRUITING","2026-05-28",{"date":69,"type":70},"2026-06-04","ACTUAL",{"date":72,"type":55},"2026-06",{"date":74,"type":55},"2029-06",{"name":5,"class":6},1]